Lanreotide: all 40 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaRecruitingNCT06807437Phase 3
• Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT05048901Phase 1/2
• Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT03043664Phase 1/2Results posted
• Lanreotide in the Treatment of Small Bowel Motility DisordersCompletedNCT03012594Phase 2Results posted
• Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 MicrospheresTerminatedNCT02859064Phase 2Results posted
• Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.CompletedNCT02698410Phase 2Results posted
• Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursTerminatedNCT02683941Phase 3Results posted
• Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With AcromegalyCompletedNCT02396953Phase 1/2Results posted
• Quality of Life in Patients With Inoperable Malignant Bowel ObstructionTerminatedNCT02365584Phase 2Results posted
• A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)TerminatedNCT02288377Phase 2/3Results posted
• Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours PatientsCompletedNCT02075606Phase 4Results posted
• A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.TerminatedNCT01861717Phase 4Results posted
• Lanreotide Autogel in the Symptomatic Treatment of Refractory DiarrheaCompletedNCT00891371Phase 2/3Results posted
• Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine TumourCompletedNCT00842348Phase 3Results posted
• An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid SyndromeCompletedNCT00774930Phase 3Results posted
• Somatuline Autogel Preference and Health Economy StudyCompletedNCT00681187Phase 4Results posted
• Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelCompletedNCT00447499Phase 3Results posted
• Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedNCT00383708Phase 3Results posted
• Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine TumoursCompletedNCT00353496Phase 3Results posted
• A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETStatus unknownNCT04427787Phase 2
• Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor LigandsCompletedNCT03967249Phase 2
• LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)Active, not recruitingNCT03946527Phase 2
• Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NETStatus unknownNCT03083210Phase 4
• The MetNET-2 TrialStatus unknownNCT02823691Early Phase 1
• Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine AnaloguesCompletedNCT02351128Phase 2
• Lanreotide In Polycystic Kidney Disease StudyCompletedNCT02127437Phase 3
• Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y GastrojejunostomyStatus unknownNCT02054637Phase 2
• SOMATULINE Autogel 90 mg IN DUMPING SYNDROMECompletedNCT01923649Phase 2
• Study of Lanreotide to Treat Polycystic Kidney DiseaseStatus unknownNCT01616927Phase 3
• Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable PatientsCompletedNCT01076803Phase 2
• Open-Label Extension of LOCKCYST TrialStatus unknownNCT00771888Phase 2/3
• Lanreotide as Treatment of Polycystic LiversCompletedNCT00565097Phase 2/3
• Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)WithdrawnNCT00517491Phase 2
• GH, IGF-I and Somatostatin Analogues in Hepatocellular CarcinomaCompletedNCT00495846Phase 2/3
• Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine TumoursCompletedNCT00326469Phase 2
• Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With AcromegalyCompletedNCT00234572Phase 2/3
• Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LARCompletedNCT00216398Phase 4
• Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal CarcinomatosisCompletedNCT00216372Phase 3
• Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsCompletedNCT00210457Phase 3
• Somatuline Autogel: Acromegaly Self/Partner Injection StudyCompletedNCT00149188Phase 4

← Lanreotide overview